These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

367 related articles for article (PubMed ID: 15180344)

  • 21. In vitro iontophoresis of R-apomorphine across human stratum corneum. Structure-transport relationship of penetration enhancement.
    Li GL; van der Geest R; Chanet L; van Zanten E; Danhof M; Bouwstra JA
    J Control Release; 2002 Nov; 84(1-2):49-57. PubMed ID: 12399167
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Understanding the poor iontophoretic transport of lysozyme across the skin: when high charge and high electrophoretic mobility are not enough.
    Dubey S; Kalia YN
    J Control Release; 2014 Jun; 183():35-42. PubMed ID: 24657950
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Pharmacokinetics, safety, and tolerability of rotigotine transdermal system in healthy Japanese and Caucasian subjects following multiple-dose administration.
    Cawello W; Kim SR; Braun M; Elshoff JP; Masahiro T; Ikeda J; Funaki T
    Eur J Drug Metab Pharmacokinet; 2016 Aug; 41(4):353-62. PubMed ID: 25773763
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Influence of hepatic impairment on the pharmacokinetics of the dopamine agonist rotigotine.
    Cawello W; Fichtner A; Boekens H; Braun M
    Eur J Drug Metab Pharmacokinet; 2014 Sep; 39(3):155-63. PubMed ID: 24052490
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Rotigotine transdermal patch for the treatment of Parkinson's disease and restless legs syndrome.
    Boroojerdi B; Wolff HM; Braun M; Scheller DK
    Drugs Today (Barc); 2010 Jul; 46(7):483-505. PubMed ID: 20683503
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Rotigotine transdermal patch for the treatment of Parkinson's Disease.
    Perez-Lloret S; Rey MV; Ratti PL; Rascol O
    Fundam Clin Pharmacol; 2013 Feb; 27(1):81-95. PubMed ID: 22320451
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Passive and iontophoretic transdermal penetration of chlorpromazine.
    Alvarez-Figueroa MJ; González-Aramundiz JV
    Pharm Dev Technol; 2008; 13(4):271-5. PubMed ID: 18649217
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Iontophoretic transdermal delivery of haloperidol.
    Alvarez-Figueroa MJ; Araya-Silva I; Díaz-Tobar C
    Pharm Dev Technol; 2006; 11(3):371-5. PubMed ID: 16895847
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Contributions of electromigration and electroosmosis to peptide iontophoresis across intact and impaired skin.
    Abla N; Naik A; Guy RH; Kalia YN
    J Control Release; 2005 Nov; 108(2-3):319-30. PubMed ID: 16169627
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Rotigotine: a novel dopamine agonist for the transdermal treatment of Parkinson's disease.
    Zareba G
    Drugs Today (Barc); 2006 Jan; 42(1):21-8. PubMed ID: 16511608
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Screening of venlafaxine hydrochloride for transdermal delivery: passive diffusion and iontophoresis.
    Singh G; Ghosh B; Kaushalkumar D; Somsekhar V
    AAPS PharmSciTech; 2008; 9(3):791-7. PubMed ID: 18592380
    [TBL] [Abstract][Full Text] [Related]  

  • 32. In vitro and in vivo iontophoretic transdermal delivery of an anti-parkinsonian agent.
    Vemulapalli V; Yang Y; Siddoju S; Conjeevaram R; Teunissen H; Myers T; Banga AK
    Int J Pharm; 2011 Nov; 420(1):20-5. PubMed ID: 21856395
    [TBL] [Abstract][Full Text] [Related]  

  • 33. No influence of the CYP2C19-selective inhibitor omeprazole on the pharmacokinetics of the dopamine receptor agonist rotigotine.
    Elshoff JP; Cawello W; Andreas JO; Braun M
    Clin Pharmacol Drug Dev; 2014 May; 3(3):187-93. PubMed ID: 27128608
    [TBL] [Abstract][Full Text] [Related]  

  • 34. In vitro iontophoretic transport of ketorolac: synthetic membrane as a barrier.
    Tiwari SB; Udupa N
    Drug Deliv; 2003; 10(3):161-8. PubMed ID: 12944136
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Combined chemical and electrical enhancement modulates stratum corneum structure.
    de Graaff AM; Li GL; van Aelst AC; Bouwstra JA
    J Control Release; 2003 Jun; 90(1):49-58. PubMed ID: 12767706
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Passive and iontophoretic permeation of glipizide.
    Jain A; Ghosh B; Rajgor N; Desai BG
    Eur J Pharm Biopharm; 2008 Aug; 69(3):958-63. PubMed ID: 18291633
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effect of charge and molecular weight on transdermal peptide delivery by iontophoresis.
    Abla N; Naik A; Guy RH; Kalia YN
    Pharm Res; 2005 Dec; 22(12):2069-78. PubMed ID: 16170597
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Rotigotine transdermal patch enables rapid titration to effective doses in advanced-stage idiopathic Parkinson disease: subanalysis of a parallel group, open-label, dose-escalation study.
    Babic T; Boothmann B; Polivka J; Rektor I; Boroojerdi B; Häck HJ; Randerath O
    Clin Neuropharmacol; 2006; 29(4):238-42. PubMed ID: 16855426
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Drug Delivery and Transport into the Central Circulation: An Example of Zero-Order In vivo Absorption of Rotigotine from a Transdermal Patch Formulation.
    Cawello W; Braun M; Andreas JO
    Eur J Drug Metab Pharmacokinet; 2018 Aug; 43(4):475-481. PubMed ID: 29332198
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Pharmacokinetic properties and tolerability of rotigotine transdermal patch after repeated-dose application in healthy korean volunteers.
    Kim BH; Yu KS; Jang IJ; Soo Lim K; Kim JR; Elshoff JP; Andreas JO; Braun M; Cawello W
    Clin Ther; 2015 Apr; 37(4):902-12. PubMed ID: 25791613
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.